NEKTAR THERAPEUTICS (NKTR)
US6402681083 - Common Stock
Overall NKTR gets a fundamental rating of 2 out of 10. We evaluated NKTR against 198 industry peers in the Pharmaceuticals industry. While NKTR seems to be doing ok healthwise, there are quite some concerns on its profitability. NKTR does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
NKTR had negative earnings in the past year.
In the past year NKTR has reported a negative cash flow from operations.
In the past 5 years NKTR always reported negative net income.
NKTR had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -69.34%, NKTR is not doing good in the industry: 67.69% of the companies in the same industry are doing better.
NKTR's Return On Equity of -210.69% is on the low side compared to the rest of the industry. NKTR is outperformed by 74.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.34% | ||
| ROE | -210.69% | ||
| ROIC | N/A |
ROA(3y)-56.02%
ROA(5y)-43.84%
ROE(3y)-129.42%
ROE(5y)-92.18%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NKTR has a better Gross Margin (62.50%) than 66.67% of its industry peers.
In the last couple of years the Gross Margin of NKTR has declined.
NKTR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.5% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.51%
GM growth 5Y-8.59%
2. Health
2.1 Basic Checks
NKTR does not have a ROIC to compare to the WACC, probably because it is not profitable.
NKTR has more shares outstanding than it did 1 year ago.
NKTR has more shares outstanding than it did 5 years ago.
NKTR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
NKTR has an Altman-Z score of -11.70. This is a bad value and indicates that NKTR is not financially healthy and even has some risk of bankruptcy.
NKTR's Altman-Z score of -11.70 is on the low side compared to the rest of the industry. NKTR is outperformed by 76.41% of its industry peers.
NKTR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -11.7 |
ROIC/WACCN/A
WACC9.25%
2.3 Liquidity
A Current Ratio of 6.45 indicates that NKTR has no problem at all paying its short term obligations.
The Current ratio of NKTR (6.45) is better than 75.38% of its industry peers.
A Quick Ratio of 6.14 indicates that NKTR has no problem at all paying its short term obligations.
The Quick ratio of NKTR (6.14) is better than 74.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.45 | ||
| Quick Ratio | 6.14 |
3. Growth
3.1 Past
NKTR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.70%, which is quite impressive.
The Revenue has decreased by -2.08% in the past year.
The Revenue for NKTR have been decreasing by -40.35% on average. This is quite bad
EPS 1Y (TTM)46.7%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q31.25%
Revenue 1Y (TTM)-2.08%
Revenue growth 3Y-16.16%
Revenue growth 5Y-40.35%
Revenue growth Q2Q8.57%
3.2 Future
NKTR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.83% yearly.
Based on estimates for the next years, NKTR will show a decrease in Revenue. The Revenue will decrease by -4.83% on average per year.
EPS Next Y14.03%
EPS Next 2Y14.36%
EPS Next 3Y10.83%
EPS Next 5YN/A
Revenue Next Year-19.8%
Revenue Next 2Y-13.99%
Revenue Next 3Y-8.93%
Revenue Next 5Y-4.83%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NKTR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NKTR. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.36%
EPS Next 3Y10.83%
5. Dividend
5.1 Amount
NKTR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NEKTAR THERAPEUTICS
NASDAQ:NKTR (4/24/2024, 7:19:20 PM)
After market: 1.3438 -0.04 (-2.62%)1.38
-0.04 (-2.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap253.40M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.34% | ||
| ROE | -210.69% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.5% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.45 | ||
| Quick Ratio | 6.14 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)46.7%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y14.03%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-2.08%
Revenue growth 3Y-16.16%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y